...
首页> 外文期刊>Current Alzheimer research >A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials
【24h】

A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials

机译:临床试验中追踪早期阿尔茨海默病的成像和神经心理学评估的生物标志物

获取原文
获取原文并翻译 | 示例

摘要

Background: Combining optimized cognitive (Alzheimer's Disease Assessment Scale-Cognitive subscale, ADAS-Cog) and atrophy markers of Alzheimer's disease for tracking progression in clinical trials may provide greater sensitivity than currently used methods, which have yielded negative results in multiple recent trials. Furthermore, it is critical to clarify the relationship among the subcomponents yielded by cognitive and imaging testing, to address the symptomatic and anatomical variability of Alzheimer's disease.
机译:背景技术结合优化的认知(Alzheimer的疾病评估规模 - 认知次级,Alzheimer疾病的用于跟踪临床试验的进展的萎缩标记可能提供比目前使用的方法更大的敏感性,这在多个最近试验中产生了负面结果。 此外,阐明认知和成像测试产生的子组件之间的关系至关重要,以解决阿尔茨海默病的症状和解剖学变异性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号